Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
In the Phase 3 POETYK PsA-2 trial, Sotyktu met its primary endpoint for treating psoriatic arthritis:
54.2% of Sotyktu-treated patients achieved ACR20 response at Week 16 vs 39.4% on placebo (p=0.0002)
Sotyktu also met key secondary endpoints, showing improvements in:
Psoriasis symptoms (PASI 75 response)
Patient-reported quality of life outcomes
Health Assessment Questionnaire-Disability Index scores
The safety profile was consistent with previous trials, with no new safety signals identified
This data supports Sotyktu's potential as the first TYK2 inhibitor for psoriatic arthritis
Sotyktu is already approved for moderate-to-severe plaque psoriasis
Bristol Myers Squibb plans to present additional data from the POETYK PsA trials later this year
The company aims to expand Sotyktu's indications to include psoriatic arthritis, pending discussions with health authorities
Sotyktu faces competition from other oral psoriatic arthritis treatments like Amgen's Otezla